Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727652 | 0.98 | HPGD (0.59) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL29809468 | 0.98 | HPGD (0.59) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7401043 | 0.86 | SMN1; SMN2 (0.55) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL17078828 | 0.85 | ALDH1A1 (0.61) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5655904 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4486004 | 0.84 | KMT2A (0.66) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL19634704 | 0.84 | HPGD (0.60) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2063259 | 0.84 | HPGD (0.62) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL10174738 | 0.84 | KMT2A (0.66) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL14637242 | 0.84 | HPGD (0.64) | HPGDSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149269-A1 | Substituted piperidine derivatives | RAE DUNCAN ROBERTSON (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20020165395-A1 | Substituted piperidine derivatives | RAE DUNCAN ROBERTSON (GB) | 2002-11-07 | — | — | US | disclosed |
| EP-0746556-B1 | TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT1A RECEPTOR | ORTHO PHARMA CORP (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020087001-A1 | Substituted piperidine derivatives | RAE DUNCAN ROBERTSON (GB) | 2002-07-04 | — | — | US | disclosed |
| EP-0563345-B1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB INC (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6365604-B1 | Antipsychotic substituted piperidine derivatives | AKZO NOBEL NV (NL) | 2002-04-02 | — | — | US | disclosed |
| CN-1274357-A | Antipsychotic substituted piperidine derivatives | AKZO NOBEL NV (NL) | 2000-11-22 | — | — | CN | disclosed |
| EP-0746556-A1 | TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT1A RECEPTOR | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5569659-A | ANTIPSYCHOTIC AGENT | MCNEILAB, INC. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5512566-A | USEFUL IN TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995011903-A1 | TRICYCLIC COMPOUNDS HAVING AFFINITY FOR THE 5-HT1A RECEPTOR | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0563345-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-10-06 | — | — | EP | disclosed |
| EP-0562049-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1993004682-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993004684-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087001-A1 | Substituted piperidine derivatives | DRD2, GRIN2C, DRD4 | HPGD 582/4885SMN1; SMN2 1790/4885NPC1 563/4885 |
| US-20030149269-A1 | Substituted piperidine derivatives | DRD2, GRIN2C, DRD4 | HPGD 582/4885SMN1; SMN2 1790/4885NPC1 563/4885 |
| US-20020165395-A1 | Substituted piperidine derivatives | DRD2, GRIN2C, DRD4 | HPGD 582/4885SMN1; SMN2 1790/4885NPC1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.